Adventris Pharmaceuticals
Adventris Pharmaceuticals, formerly known as Elimivax, is a healthcare company specializing in cancer immunotherapy and vaccine development for lung cancer targeting the KRAS mutation.
Company History
Adventris Pharmaceuticals, previously known as Elimivax, has established its presence in the healthcare industry specializing in drug discovery and delivery. The company is part of the Winter 2023 Y-Combinator batch, marking it as a participant in one of the most prestigious startup accelerators.
Locations
Adventris Pharmaceuticals operates out of two primary locations: Baltimore, MD, and San Francisco, CA. These strategic locations help bridge their research and development activities on both the East and West Coasts of the United States. The team also works partly remote, accommodating a flexible work environment that spans across the USA and Canada.
Industry and Sub-Industry
Adventris Pharmaceuticals is part of the healthcare industry, specifically focusing on drug discovery and delivery. Their specialized work targets cancer immunotherapy, with a significant emphasis on developing vaccines aimed at treating lung cancer caused by the KRAS mutation.
Cancer Immunotherapy Focus
The core focus of Adventris Pharmaceuticals is on cancer immunotherapy. The company develops vaccines designed to treat lung cancer by targeting the KRAS mutation. Their vision includes creating annual vaccines for adults to prevent the majority of cancer deaths, aiming for significant advancements in cancer prevention.
Partnership Opportunities
Adventris Pharmaceuticals offers various partnership opportunities. Whether through research collaborations, clinical trials, or strategic alliances, the company is open to partnering with organizations and institutions that share their goal of advancing cancer immunotherapy and preventative healthcare.